Watch KNSA. Know when insiders buy.
One email the day a filing lands. Free.
KNSA
Kiniksa Pharmaceuticals International, plc
77.91
−2.56 −3.18%
USD · Sep 6, 01:16 a.m. ET
Work order
43
WATCH · insiders 34, shorts 52
Insiders, 90 days
−$369K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E 85.6DIV YIELD —FCF YIELD —REV TTM $754M +56.7%NET INCOME $73.1MNET CASH —52W 35.42 – 80.92SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2026 · Mar 31 | $214.3M | +55.5% | 90.3% | $29.3M | $22.6M | +164.6% | 0.27 | $50.2M | $161K | $50M | Apr 28 |
| Q4 2025 · Dec 31derived | $202.1M | +65.0% | 89.6% | $19.8M | $14.2M | — | 0.18 | $53.9M | $633K | $53.3M | Feb 24 |
| Q3 2025 · Sep 30 | $180.9M | +61.2% | 88.8% | $24M | $18.4M | — | 0.23 | $33.7M | $671K | $33M | Oct 28 |
| Q2 2025 · Jun 30 | $156.8M | +44.3% | 88.1% | $20.2M | $17.8M | — | 0.23 | $28.1M | $165K | $27.9M | Oct 28 |
| Q1 2025 · Mar 31 | $137.8M | +72.5% | 87.0% | $13.3M | $8.5M | — | 0.11 | $22.3M | $99K | $22.2M | Apr 28 |
| Q4 2024 · Dec 31derived | $122.5M | +46.9% | 85.4% | −$19.3M | −$8.9M | −135.2% | -0.12 | $18.8M | $193K | $18.6M | Feb 24 |
| Q3 2024 · Sep 30 | $112.2M | +67.4% | 82.1% | −$9.7M | −$12.7M | — | -0.18 | −$2.2M | $0 | −$2.2M | Oct 28 |
| Q2 2024 · Jun 30 | $108.6M | +52.0% | 88.7% | −$117K | −$3.9M | −126.1% | -0.06 | $5.2M | $0 | $5.2M | Oct 28 |
| Q1 2024 · Mar 31 | $79.9M | — | 86.7% | −$16.5M | −$17.7M | — | -0.25 | $4M | $84K | $3.9M | Oct 28 |
| Q4 2023 · Dec 31derived | $83.4M | — | 88.5% | $81K | $25.2M | — | 0.36 | $4.3M | $56K | $4.3M | Feb 24 |
| Q3 2023 · Sep 30 | $67M | — | 86.4% | −$10.9M | −$13.9M | — | -0.20 | $17M | $16K | $17M | Oct 29 |
| Q2 2023 · Jun 30 | $71.5M | — | 89.2% | −$3.2M | $15M | — | 0.21 | −$3.7M | $34K | −$3.8M | Oct 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $677.6M | 88.5% | $77.2M | $59M | 8.7% | 0.75 | $138M | $1.6M | $136.4M | — | — |
| FY2024 · to Dec 31 | $423.2M | 85.6% | −$45.6M | −$43.2M | -10.2% | -0.60 | $25.7M | $277K | $25.4M | — | — |
| FY2023 · to Dec 31 | $270.3M | 87.6% | −$25.2M | $14.1M | 5.2% | 0.20 | $13.3M | $130K | $13.2M | — | — |
| FY2022 · to Dec 31 | $220.2M | 89.6% | $9.8M | $183.4M | 83.3% | 2.60 | $5.8M | $105K | $5.7M | — | — |
| FY2021 · to Dec 31 | $38.5M | 76.4% | −$156.6M | −$157.9M | -409.7% | -2.30 | −$126.3M | $415K | −$126.7M | — | — |
| FY2020 · to Dec 31 | — | — | −$157.4M | −$161.4M | — | -2.61 | −$136.5M | $283K | −$136.8M | — | — |
Every number comes from Kiniksa Pharmaceuticals International, plc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.